Keri Dillon, APRN
Primary Care · Omaha, NENPI 1093196909
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $633 and has fallen 54.1% since, to $291 in 2025.
Across 116 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$476
- Lilly USA, LLC$297
- Novo Nordisk$294
- AbbVie$274
- Aimmune Therapeutics, Inc.$112
- AstraZeneca$111
- plus $678 from 22 others
What the payments were for
- Food & beverage$2,241100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 31 | $476 |
| Lilly USA, LLC | 12 | $297 |
| Novo Nordisk | 23 | $294 |
| AbbVie | 9 | $274 |
| Aimmune Therapeutics, Inc. | 1 | $112 |
| AstraZeneca | 6 | $111 |
| Nestle Healthcare Nutrition Inc. | 3 | $88 |
| Medtronic | 3 | $66 |
| Amgen | 4 | $61 |
| Procept Biorobotics Corporation | 1 | $60 |
| Exact Sciences | 3 | $46 |
| Grifols USA, LLC | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Mylan Specialty L.p. | 1 | $24 |
| Sanofi | 1 | $21 |
| GSK | 1 | $21 |
| Boston Scientific | 1 | $21 |
| Abbott | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Bayer | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,241 in reported general payments places this provider in the 85th percentile of 65 primary care providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 54 | $58,519 |
| JardianceEmpagliflozin | 22 | $25,159 |
| OzempicSemaglutide | 20 | $18,490 |
| MyrbetriqMirabegron | 24 | $16,893 |
| XareltoRivaroxaban | 16 | $13,591 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $10,346 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $7,468 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 107 | $2,534 |
| Levothyroxine Sodium | 291 | $2,532 |
| Omeprazole | 173 | $2,347 |
| Metoprolol Succinate | 213 | $2,246 |
| Gabapentin | 71 | $1,909 |
| Atorvastatin Calcium | 232 | $1,878 |
| Amlodipine Besylate | 372 | $1,776 |
| Raloxifene Hcl | 21 | $1,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $476 | $58,51954 claims |
| Boehringer IngelheimJardiance | $17 | $25,15922 claims |
| Novo NordiskOzempic | $294 | $18,49020 claims |
| AstraZenecaBreztri Aerosphere | $111 | $10,34615 claims |
| AbbVieSynthroid | $274 | $96519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 65 primary care providers in Nebraska.
Other primary care in Omaha
- Jenna KoppOmaha$141K
- Alexis BarbosaOmaha$7K
- Rabia MoukradOmaha$6K
- Joseph AnthoneOmaha$2K
- Julie HuttonOmaha$2K
- Michelle PlacekOmaha$1K
- Johnna FeikOmaha$970
- Rasila Soumana HamaOmaha$732
- Tiffany BartekOmaha$643
- Nichole ThiesOmaha$628
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.